Compare Procter & Gamble Health with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs LUPIN - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH LUPIN PROCTER & GAMBLE HEALTH/
LUPIN
 
P/E (TTM) x 52.7 47.5 111.0% View Chart
P/BV x 4.8 2.4 195.9% View Chart
Dividend Yield % 10.0 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   LUPIN
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
LUPIN
Mar-19
PROCTER & GAMBLE HEALTH/
LUPIN
5-Yr Chart
Click to enlarge
High Rs3,549986 359.9%   
Low Rs1,301720 180.6%   
Sales per share (Unadj.) Rs511.4369.5 138.4%  
Earnings per share (Unadj.) Rs61.313.4 457.2%  
Cash flow per share (Unadj.) Rs74.037.4 198.0%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.8303.7 305.5%  
Shares outstanding (eoy) m16.60452.49 3.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.3 205.3%   
Avg P/E ratio x39.663.6 62.2%  
P/CF ratio (eoy) x32.822.8 143.6%  
Price / Book Value ratio x2.62.8 93.0%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,257386,064 10.4%   
No. of employees `0001.117.7 6.4%   
Total wages/salary Rs m1,31331,513 4.2%   
Avg. sales/employee Rs Th7,486.79,453.8 79.2%   
Avg. wages/employee Rs Th1,157.61,782.0 65.0%   
Avg. net profit/employee Rs Th897.2343.0 261.6%   
INCOME DATA
Net Sales Rs m8,490167,182 5.1%  
Other income Rs m2443,640 6.7%   
Total revenues Rs m8,734170,822 5.1%   
Gross profit Rs m1,48228,822 5.1%  
Depreciation Rs m21110,850 1.9%   
Interest Rs m03,078 0.0%   
Profit before tax Rs m1,51418,534 8.2%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m66-3,400 -1.9%   
Tax Rs m5639,017 6.2%   
Profit after tax Rs m1,0176,066 16.8%  
Gross profit margin %17.517.2 101.2%  
Effective tax rate %37.148.7 76.4%   
Net profit margin %12.03.6 330.3%  
BALANCE SHEET DATA
Current assets Rs m15,343138,536 11.1%   
Current liabilities Rs m1,96061,299 3.2%   
Net working cap to sales %157.646.2 341.2%  
Current ratio x7.82.3 346.3%  
Inventory Days Days4984 58.2%  
Debtors Days Days28112 25.3%  
Net fixed assets Rs m1,209127,516 0.9%   
Share capital Rs m166905 18.3%   
"Free" reserves Rs m15,235136,517 11.2%   
Net worth Rs m15,401137,422 11.2%   
Long term debt Rs m066,417 0.0%   
Total assets Rs m17,595279,494 6.3%  
Interest coverage xNM7.0-  
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.50.6 80.7%   
Return on assets %5.83.3 176.7%  
Return on equity %6.64.4 149.7%  
Return on capital %10.38.9 115.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63659,414 2.8%   
Fx outflow Rs m4,36822,282 19.6%   
Net fx Rs m-2,73237,132 -7.4%   
CASH FLOW
From Operations Rs m-1,30416,660 -7.8%  
From Investments Rs m12,697-32,825 -38.7%  
From Financial Activity Rs m-3017,441 -4.0%  
Net Cashflow Rs m11,093-8,724 -127.2%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 51.8 0.2 25,900.0%  
Indian inst/Mut Fund % 18.2 11.3 161.1%  
FIIs % 1.0 31.9 3.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 10.1 288.1%  
Shareholders   28,591 98,259 29.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 18, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS